MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Go back to MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
(NASDAQ: MTVA) Delayed: 1.67 -0.06 (3.47%)
Previous Close $1.73    52 Week High
Open $1.65    52 Week Low
Day High $1.70    P/E N/A 
Day Low $1.64    EPS
Volume 45,290